Sideris Pharmaceuticals is a biopharmaceutical company focused on the development of new treatments for transfusion related iron overload
Sideris’ lead clinical candidate, SP-420, is designed to be a best-in-class oral iron chelator.
We are advancing SP-420 on a well-defined clinical development path to meet the significant medical need for improved iron chelation medicines.
January 7, 2014, Sideris Pharmaceuticals Appoints Gregory I. Berk, M.D., as President and Chief Medical Officer
October 22, 2013, Sideris Completes $32M Equity Financing and Signs Agreement with Global Pharmaceutical Company.